Analysis of NR2A-CREB-BDNF Signaling Pathway in Stroke

In ischemic stroke, synaptic NMDAR activation and Ca²⁺ influx activate the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and nuclear Ca²⁺/calmodulin-dependent protein kinases, which in turn phosphorylate and activate cAMP-response element-binding protein (CREB). Activated CREB upregulates brain-derived neurotrophic factor (BDNF) activity and promotes the expression of numerous pro-neuronal survival genes. In conclusion, BDNF and the upstream CREB signaling pathway play a crucial role in promoting cell proliferation and survival, and preventing acute cerebral ischemic damage. The NR2A-CREB-BDNF-TrkB signaling pathway is a key target for actionable ischemic stroke therapy.

Fig. 1. Synaptic activity mediates prolonged neuronal survival via a positive feedback loop between CREB and BDNF. (Lai et al., 2014)

Our Services

At Ace Therapeutics, we specialize in analyzing the NR2A-CREB-BDNF signaling pathway in stroke. We aim to help our clients discover and validate effective targets to protect neurons from post-ischemic stroke excitotoxicity by promoting the NR2A-CREB-BDNF-TrkB signaling pathway.

Our team of experienced researchers and scientists conducts comprehensive analyses using state-of-the-art techniques to elucidate the role of NR2A-CREB-BDNF signaling in stroke and develop potential therapeutic targets. Our research focuses on the following targets:

Workflow of NR2A-CREB-BDNF Signaling Pathway Analysis

• Experimental design: We carefully designed experiments to investigate the involvement of NR2A, CREB, and BDNF in the pathogenesis of stroke. This includes appropriate animal models of stroke selection, sample collection, and endpoints measurement.
• Molecular analysis: We provide protein blotting, immunohistochemistry, and quantitative polymerase chain reaction (qPCR) techniques to assess the expression levels and activation status of NR2A, CREB, and BDNF in experimental models of stroke.
• Functional studies: We conduct functional studies ( e.g. behavioral assessments, histological analyses, and brain imaging) to assess the effect of stroke drugs that modulate the NR2A-CREB-BDNF signaling pathway on stroke outcomes.
• Data analysis: We use advanced bioinformatics tools and statistical analyses to interpret the data obtained from our experiments. We provide you with complete raw data and detailed report analysis.

With our expertise, state-of-the-art facilities, and collaborative approach, Ace Therapeutics is committed to helping customers discover and validate effective targets to target neuro-excitotoxicity in stroke. If you are interested in our services, please do not hesitate to contact us!

1. Lai, T. W., et al. (2014). Excitotoxicity and stroke: identifying novel targets for neuroprotection. Progress in neurobiology, 115, 157-188.